Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
COMPUGEN LTD (CGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/23/2023 20-F/A Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
08/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Notice of 2023 annual general meeting of shareholders of Compugen Ltd., proxy statement and proxy card",
"Notice of 2023 annual general meeting of shareholders of Compugen Ltd., proxy statement and proxy card"
08/07/2023 6-K Quarterly results
Docs: "6-K",
"Compugen Reports Second Quarter 2023 Results",
"F-2 - F-3 Condensed Consolidated Statements of Comprehensive Loss F-4 Condensed Consolidated Statements of Changes in Shareholders' Equity F-5 Condensed Consolidated Statements of Cash Flows F-6 Notes to Condensed Consolidated Financial Statements F-7 - F-15",
"MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION"
06/13/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement"
05/15/2023 6-K Quarterly results
Docs: "6-K",
"Compugen Reports First Quarter 2023 Results"
05/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
04/14/2023 F-3/A Form F-3/A - Registration statement by foreign private issuers: [Amend]
03/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
03/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof of Concept Study",
"Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof of Concept Study"
02/28/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
02/27/2023 6-K Quarterly results
Docs: "6-K",
"Compugen Reports Fourth Quarter and Full Year 2022 Results"
02/14/2023 6-K Quarterly results
02/10/2023 SC 13G/A Nikko Asset Management Americas, Inc. reports a 0% stake in Compugen, Ltd.
02/03/2023 SC 13G/A Sumitomo Mitsui Trust Holdings, Inc. reports a 0% stake in Compugen, Ltd.
01/31/2023 6-K Quarterly results
01/31/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/06/2022 6-K Quarterly results
12/02/2022 6-K Quarterly results
12/01/2022 6-K Quarterly results
11/16/2022 6-K Quarterly results
11/14/2022 6-K Quarterly results
11/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Compugen’s COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients",
"Compugen’s COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients"
11/02/2022 6-K Quarterly results
09/22/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Compugen Letter to Shareholders"
09/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
09/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer"
08/04/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/04/2022 6-K Quarterly results
08/04/2022 6-K Quarterly results
08/04/2022 6-K Quarterly results
08/04/2022 6-K Quarterly results
05/16/2022 6-K Quarterly results
05/10/2022 6-K Quarterly results
02/28/2022 20-F/A Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy